Supriya Lifescience

Supriya Lifescience Rule of 40

The Rule of 40 of Supriya Lifescience (SUPRIYA.NS) as of Nov 4, 2026 is 52.28 %. In the previous year, Rule of 40 was 58.04 % — a change of -9.91% (lower).

Rule of 40

52.28 %

YoY

-9.91%

Last updated:

Rule of 40 of Supriya Lifescience is 2026 52.28 % . Rule of 40 of Supriya Lifescience was 2025 58.04 % . It decreases by -9.91% lower compared to the previous year.

The Supriya Lifescience Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2019
52.48 INR
Jan 1, 2020
46.01 INR
Jan 1, 2021
66.33 INR
Jan 1, 2022
75.49 INR
Jan 1, 2023
14.59 INR
Jan 1, 2024
55.87 INR
Jan 1, 2025
58.04 INR
Jan 1, 2026
52.28 INR
The Supriya Lifescience Rule of 40 history
YEARRule of 40YoY
52.28 %-9.91%
58.04 %+3.87%
55.87 %+282.93%
14.59 %-80.67%
75.49 %+13.81%
66.33 %+44.14%
46.01 %-12.33%
52.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Supriya Lifescience Stock analysis

What does Supriya Lifescience do? Supriya Lifescience Ltd. generates revenue through the manufacturing and export of active pharmaceutical ingredients (APIs) focused on niche therapeutic segments. The company produces approximately 38 API products, including Chlorphenamine Maleate, Pheniramine Maleate, and Cetirizine DiHCL, which address antihistamine, analgesic, vitamin, anesthetics, and anti-asthma therapies. These products are exported to around 86 countries, targeting pharmaceutical manufacturers and healthcare providers seeking specialized chemical compounds for drug formulations. The firm's manufacturing facilities in Maharashtra support the production of bulk drugs and pharmaceutical chemicals, with a strong emphasis on research and development to maintain its niche market position. The company's product portfolio includes specialized compounds such as Bisoprolol Fumarate, Nicorandil, and Mecobalamin, which cater to specific medical needs in cardiovascular and neurological treatments. By concentrating on high-demand therapeutic areas like antihistamines and anti-asthma solutions, Supriya Lifescience Ltd. serves pharmaceutical companies globally that require reliable sources of API raw materials. Its export-driven model ensures steady demand from international clients across diverse healthcare markets. Supriya Lifescience Ltd. leverages its research and development capabilities to develop and refine its API offerings, ensuring compliance with global pharmaceutical standards. The firm's focus on niche products allows it to differentiate itself in a competitive market, attracting buyers who prioritize specialized chemical solutions over generic alternatives. With a manufacturing base in Maharashtra, the company efficiently scales production to meet the growing global demand for its targeted therapeutic APIs. Supriya Lifescience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Supriya Lifescience stock

Rule of 40 of Supriya Lifescience is 52.28 % in 2026.

On Eulerpool you can find the complete historical development of Rule of 40 Supriya Lifescience since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Supriya Lifescience

All Key Metrics — Supriya Lifescience